Backed by €15 million in EU funding, the Ubiquitous Pharmacogenomics Consortium seeks to implement preemptive testing at seven healthcare systems by 2020.
The partners will evaluate several quality control assays for genome editing research, eventually creating a protocol for analyzing mutations in genomic DNA.
LGC said it plans to use Douglas Scientific's PCR and qPCR platforms to provide customers with enhanced high-throughput genotyping and qPCR instruments.
